Human papillomavirus vaccination for adults aged 30 to 45 years in the United States: A cost-effectiveness analysis.
<h4>Background</h4>A nonavalent human papillomavirus (HPV) vaccine has been licensed for use in women and men up to age 45 years in the United States. The cost-effectiveness of HPV vaccination for women and men aged 30 to 45 years in the context of cervical cancer screening practice was...
Enregistré dans:
| Auteurs principaux: | , , , , , , , |
|---|---|
| Format: | article |
| Langue: | EN |
| Publié: |
Public Library of Science (PLoS)
2021
|
| Sujets: | |
| Accès en ligne: | https://doaj.org/article/c7a9a728c2a34564b00d467c9944ca6f |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|